Madrigal Pharmaceuticals, Inc. News Releases https://ir.madrigalpharma.com/ Madrigal Pharmaceuticals, Inc. News Releases en Madrigal Pharmaceuticals Reports 2019 First Quarter Financial Results and Highlights https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-2019-first-quarter-financial CONSHOHOCKEN, Pa. , May 08, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2019 financial results and highlights: “Madrigal continued to make significant progress in the first quarter of 2019, initiating a Phase 3 study of MGL-3196 Wed, 08 May 2019 06:50:00 -0400 Madrigal Pharmaceuticals, Inc. News Releases 13061 Madrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress™ 2019 https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-present-additional-analyses-data-phase -- MRI-PDFF response (≥30% reduction in hepatic fat) at 12 weeks correlated with reduction in the ballooning and inflammation components of NAS and was predictive of NASH resolution on liver biopsy at 36 weeks --        -- The data suggest that reduction of hepatic fat is a critical component of Mon, 08 Apr 2019 06:50:00 -0400 Madrigal Pharmaceuticals, Inc. News Releases 13041 Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis a https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-initiates-phase-3-multinational-double -- Investigator meeting held March 21/22, 2019 -- -- In Phase 2 study resmetirom was statistically significantly superior to placebo in resolving NASH on biopsy, appeared safe and was well-tolerated -- CONSHOHOCKEN, Pa. , March 28, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. Thu, 28 Mar 2019 06:50:00 -0400 Madrigal Pharmaceuticals, Inc. News Releases 13036 Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-2018-fourth-quarter-and-full CONSHOHOCKEN, Pa. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2018 financial results and highlights: “Madrigal made significant progress in 2018 in advancing the development of MGL-3196. Wed, 27 Feb 2019 06:50:00 -0500 Madrigal Pharmaceuticals, Inc. News Releases 13006 Phase 2 Results for Madrigal’s MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting® 2018 https://ir.madrigalpharma.com/news-releases/news-release-details/phase-2-results-madrigals-mgl-3196-non-alcoholic-steatohepatitis -- Statistically significantly more NASH resolution in MGL-3196 as compared with placebo in a Phase 2 clinical trial support MGL-3196 as a first- and potentially best-in class thyroid hormone receptor (THR) β-selective agonist for treating patients with NASH --The fact that MGL-3196 lowers LDL Mon, 12 Nov 2018 11:30:00 -0500 Madrigal Pharmaceuticals, Inc. News Releases 12941 Madrigal Pharmaceuticals Reports 2018 Third Quarter Financial Results and Highlights Upcoming Clinical Events https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-2018-third-quarter-financial CONSHOHOCKEN, Pa. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2018 financial results and described upcoming clinical events: “Madrigal made important progress thus far in 2018 to advance the development of MGL-3196, through Tue, 06 Nov 2018 06:50:00 -0500 Madrigal Pharmaceuticals, Inc. News Releases 12931 Madrigal Pharmaceuticals Reports 2018 Second Quarter Financial Results and Reviews Key Clinical Achievements https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-2018-second-quarter-financial Madrigal’s MGL-3196 NASH abstract selected for oral presentation in the presidential plenary clinical session of The Liver Meeting® 2018 during the American Association for the Study of Liver Diseases 2018 Annual Meeting CONSHOHOCKEN, Pa. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Madrigal Tue, 07 Aug 2018 06:50:00 -0400 Madrigal Pharmaceuticals, Inc. News Releases 12896 Madrigal Pharmaceuticals Prices Public Offering of Common Stock https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-prices-public-offering-common-stock-0 CONSHOHOCKEN, Pa. , June 06, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, Wed, 06 Jun 2018 23:14:00 -0400 Madrigal Pharmaceuticals, Inc. News Releases 12821 Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-proposed-public-offering-0 CONSHOHOCKEN, Pa. , June 05, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, Tue, 05 Jun 2018 16:10:00 -0400 Madrigal Pharmaceuticals, Inc. News Releases 12806 Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial https://ir.madrigalpharma.com/news-releases/news-release-details/madrigals-mgl-3196-achieves-liver-biopsy-endpoints-patients-non -- Statistically significantly more patients treated with MGL-3196 compared with placebo treated patients achieved a two point reduction in NAS (NAFLD activity score) on biopsy -- -- Statistically significantly more patients treated with MGL-3196 compared with placebo treated patients achieved Thu, 31 May 2018 06:50:00 -0400 Madrigal Pharmaceuticals, Inc. News Releases 12791